- Expansion of existing partnership covering neuromuscular indications to now include CNS indications in neurodegeneration
- PeptiDream is eligible to receive up to approximately $3.5 billion in total, as upfront and potential preclinical / clinical / launch / sales-based milestones, excluding royalty payments
PeptiDream Inc. (Representative Director and President: Patrick C. Reid; Head Office: Kawasaki City, Kanagawa Prefecture; "PeptiDream") and Takeda Pharmaceutical Company Limited ("Takeda") announced today an expansion of its research collaboration and exclusive license agreement to create peptide-drug conjugates (PDCs) for several central nervous system (CNS) targets, which play important roles in chronic neurodegenerative diseases.
PeptiDream and Takeda originally entered into a collaborative research and exclusive license agreement
in December 2020 to create PDCs for neuromuscular diseases by conjugating peptides developed by PeptiDream and JCR Pharmaceuticals Co., Ltd. that bind to human transferrin receptor 1 (TfR1) to specific drug payloads selected by Takeda. This new collaboration expands the use of the TfR1 binding peptide ligands for CNS targets associated with neurodegeneration allowing Takeda to conjugate the peptides with therapeutic cargoes optimized to cross the blood-brain barrier (BBB).
A significant challenge to the development of effective medicines for neurodegenerative diseases is the ability to deliver therapeutic molecules across the BBB into the brain. Peptide carriers that bind to TfR1 when conjugated to various therapeutic payloads facilitate the transport of the payload across the BBB into the brain, and thereby significantly improve functional benefit. This TfR1 BBB shuttle approach has the potential to accelerate the development of therapies for which BBB penetration remains challenging. This approach may also enable broad brain region biodistribution that is frequently needed to effectively treat many neurodegenerative diseases for which few, if any, effective drugs currently exist.
“We have made great progress since initiating our research collaboration with PeptiDream for neuromuscular disease in December 2020, which served as the catalyst for this expansion into programs focusing on neurodegeneration. PeptiDream’s TfR1 binding technology holds great promise for tackling the biodistribution challenges needed to develop effective therapies for complex neurological disorders,” said Sarah Sheikh, Head, Neuroscience Therapeutic Area Unit at Takeda. “This collaboration demonstrates Takeda’s commitment to cutting edge neuroscience whether it resides within Takeda or the labs of our partners where we can combine their strengths with our own world-class research laboratories in Shonan, Japan.”
Keiichi Masuya, Executive Vice President at PeptiDream, said the following. “We are very pleased to be able to further expand our efforts with Takeda using TfR1 binding peptides. Through these efforts we hope to contribute to the acceleration of innovative new drug development, by improving the efficiency of uptake of drugs into the brain—which has been a problem in the past—and lowering a major hurdle to drug development for CNS diseases. We are very much looking forward to starting collaborations with Takeda researchers, not only in the area of neuromuscular diseases, but also CNS diseases.”
Under the terms of the agreement, PeptiDream is eligible to receive up to approximately $3.5 billion (JPY 390.3 billion*1
) in total as upfront and potential preclinical, development, launch, and sales-based milestones. In addition to the above, PeptiDream is also eligible to receive royalties on net sales of any product resulting from the collaboration.
*1: USD/ JPY currency conversion rate: 111.5About PeptiDream Inc.
PeptiDream Inc. employs its proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based, small molecule-based or peptide-drug conjugate therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit https://www.peptidream.com
.About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com
Contact: Yuko Okimoto, IR & Public Affairs
Email: [email protected]Takeda Pharmaceutical Company Limited
R&D Communication, Japan-APAC
Contact: Ritsuko Nomura
Email: [email protected]
Global Corporate Affairs
Contact: Ryoko Matsumoto
Email: [email protected]